Monday Lecture Series
Contributions of Gene Variants, Endorphins, and Stress Responsivity to Specific Addictions
Mary Jeanne Kreek, MD
Laboratory of the Biology of Addictive Diseases
The Rockefeller University
November 8, 2010
4:15 p.m. Caspary Hall
Schwarzer C. 2009. 30 years of dynorphins – New insights on their functions in neuropsychiatric diseases. PHARMACOLOGY & THERAPEUTICS 123(3):353-370 Please request from Markus Library.
Shin AC, Pistell PJ, Phifer CB, et al. 2010. Reversible suppression of food reward behavior buy chronic mu-opioid receptor antagonism in the nucleus accumbens. NEUROSCIENCE 170(2): 580-588
Mizoguchi H, Watanabe C, Osada S, et al. 2010. Lack of a rewarding effect and a locomotor-enhancing effect of the selective mu-opioid receptor agonist amidino-TAPA. PSYCHOPHARMACOLOGY 212(2): 215-225
Mague SD, Blendy JA. 2010. OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models. DRUG AND ALCOHOL DEPENDENCE 108(3, Special Issue SI): 172-182 Request from Markus Library.
Kreek MJ. 2010. Overview and historical perspective of four papers presented on research related to the endogenous opioid system. DRUG AND ALCOHOL DEPENDENCE 10(3, Special Issue SI): 195-199 Request from Markus Library.
Bruchas MR, Land BB, Chavkin C. 2010. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. BRAIN RESEARCH 1314( Special Issue SI): 44-55
Zhou Y, Proudnikov D, Yuferov V, et al. 2010. Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. BRAIN RESEARCH 1314(Special Issue SI): 235-252
Kreek MJ, Zhou Y, Butelman ER, et al. 2009. Opiate and cocaine addiction: from bench to clinic and back to the bench. CURRENT OPINION IN PHARMACOLOGY 9(1): 74-80